• Hunan Pharmaceutical Development PE Fund’s Gaoxin Zongheng-backed Microyu Tiandao cleared a key review for a sale to listed Chuangyuan Xinke.
• Beijing Stock Exchange’s M&A committee passed Chuangyuan Xinke’s deal on Sept. 8, 2026, using shares and cash for 100% of Microyu Tiandao.
• Microyu Tiandao will become a wholly owned unit, expanding Chuangyuan Xinke into satellite navigation simulation and testing alongside its RF testing franchise.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hunan Pharmaceutical Development Private Equity Fund Management Co Ltd published the original content used to generate this news brief on September 12, 2026, and is solely responsible for the information contained therein.